| Colton Clinica Medica Familiar | |
|
301 S La Cadena Dr Colton CA 92324-3419 | |
| (909) 219-5093 | |
| (909) 219-5260 |
| Full Name | Colton Clinica Medica Familiar |
|---|---|
| Speciality | Family Medicine |
| Location | 301 S La Cadena Dr, Colton, California |
| Authorized Official Name and Position | Octavio Ruiz-villalpando (OWNER/PRESIDENT) |
| Authorized Official Contact | 9512854393 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Colton Clinica Medica Familiar 301 S La Cadena Dr Colton CA 92324-3419 Ph: (909) 219-5093 | Colton Clinica Medica Familiar 301 S La Cadena Dr Colton CA 92324-3419 Ph: (909) 219-5093 |
| NPI Number | 1114374071 |
|---|---|
| Provider Enumeration Date | 05/20/2016 |
| Last Update Date | 05/20/2016 |
| Medicare PECOS PAC ID | 9032542667 |
|---|---|
| Medicare Enrollment ID | O20191211003320 |
News Archive
Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has been notified that it has been awarded approximately $489,000 total in two federal grants under the Qualifying Therapeutic Discovery Project ("QTDP") Program.
EHRA-Europace and Cardiostim, Europe's leading congresses in "electrophysiology" and the treatment of heart rhythm disorders have formed a strategic alliance to ensure the development from year to year of a homogeneous congress programme devised under the direction of a common scientific committee.
A new study produced by an interdisciplinary team led by Prof. Antonio Giordano, director of the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University, tracks the development process and efficacy of the Italian translation of the Derriford Appearance Scale 24, an important clinical tool in identifying quality-of-life issues for breast cancer patients, especially concerns regarding body shame, depression, anxiety, overall appearance and appearance identity.
GeNeuro SA, a pioneer of new therapies for neurology and autoimmune disorders, announced today that it has initiated its planned Phase IIb study "CHANGE-MS" (Clinical trial assessing the HERV-W Env ANtagonist GNbAC1 for Efficacy in Multiple Sclerosis) with its lead antibody GNbAC1 in Relapsing-Remitting Multiple Sclerosis (RRMS).
While current medications for Alzheimer's disease are effective for some patients in slowing the rate of AD progression, many patients do not benefit from the treatments or cannot tolerate them, says lead researcher Michelle M. Mielke, Ph.D., of the Department of Psychiatry and Behavioral Sciences at The Johns Hopkins University School of Medicine.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114374071 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | A92039 (California) | Primary |
| Provider Name | Octavio Ruiz Villalpando |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1194832816 PECOS PAC ID: 3870691926 Enrollment ID: I20070613000358 |
News Archive
Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has been notified that it has been awarded approximately $489,000 total in two federal grants under the Qualifying Therapeutic Discovery Project ("QTDP") Program.
EHRA-Europace and Cardiostim, Europe's leading congresses in "electrophysiology" and the treatment of heart rhythm disorders have formed a strategic alliance to ensure the development from year to year of a homogeneous congress programme devised under the direction of a common scientific committee.
A new study produced by an interdisciplinary team led by Prof. Antonio Giordano, director of the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University, tracks the development process and efficacy of the Italian translation of the Derriford Appearance Scale 24, an important clinical tool in identifying quality-of-life issues for breast cancer patients, especially concerns regarding body shame, depression, anxiety, overall appearance and appearance identity.
GeNeuro SA, a pioneer of new therapies for neurology and autoimmune disorders, announced today that it has initiated its planned Phase IIb study "CHANGE-MS" (Clinical trial assessing the HERV-W Env ANtagonist GNbAC1 for Efficacy in Multiple Sclerosis) with its lead antibody GNbAC1 in Relapsing-Remitting Multiple Sclerosis (RRMS).
While current medications for Alzheimer's disease are effective for some patients in slowing the rate of AD progression, many patients do not benefit from the treatments or cannot tolerate them, says lead researcher Michelle M. Mielke, Ph.D., of the Department of Psychiatry and Behavioral Sciences at The Johns Hopkins University School of Medicine.
› Verified 7 days ago
News Archive
Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has been notified that it has been awarded approximately $489,000 total in two federal grants under the Qualifying Therapeutic Discovery Project ("QTDP") Program.
EHRA-Europace and Cardiostim, Europe's leading congresses in "electrophysiology" and the treatment of heart rhythm disorders have formed a strategic alliance to ensure the development from year to year of a homogeneous congress programme devised under the direction of a common scientific committee.
A new study produced by an interdisciplinary team led by Prof. Antonio Giordano, director of the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University, tracks the development process and efficacy of the Italian translation of the Derriford Appearance Scale 24, an important clinical tool in identifying quality-of-life issues for breast cancer patients, especially concerns regarding body shame, depression, anxiety, overall appearance and appearance identity.
GeNeuro SA, a pioneer of new therapies for neurology and autoimmune disorders, announced today that it has initiated its planned Phase IIb study "CHANGE-MS" (Clinical trial assessing the HERV-W Env ANtagonist GNbAC1 for Efficacy in Multiple Sclerosis) with its lead antibody GNbAC1 in Relapsing-Remitting Multiple Sclerosis (RRMS).
While current medications for Alzheimer's disease are effective for some patients in slowing the rate of AD progression, many patients do not benefit from the treatments or cannot tolerate them, says lead researcher Michelle M. Mielke, Ph.D., of the Department of Psychiatry and Behavioral Sciences at The Johns Hopkins University School of Medicine.
› Verified 7 days ago
John F. Randolph,m.d.,inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 400 North Pepper Avenue, Colton, CA 92324 Phone: 909-580-1675 Fax: 909-580-1916 | |
Molina Medical Centers Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1001 E Cooley Dr Ste 106, Colton, CA 92324 Phone: 909-825-8373 Fax: 909-825-3276 | |
Lizarraga Medical Clinic Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 895 W Valley Blvd, Colton, CA 92324 Phone: 909-824-3389 | |
Mt. Vernon Medical Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1023 S Mount Vernon Ave, Colton, CA 92324 Phone: 909-422-8015 Fax: 909-422-0625 | |
Inland Empire Medical Group Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1550 E Washington St # 101, Colton, CA 92324 Phone: 800-418-0850 | |
Arrowhead Family Medical Group Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 400 N Pepper Ave, Colton, CA 92324 Phone: 909-580-6230 Fax: 909-580-6308 |